11:32 AM EDT, 10/08/2024 (MT Newswires) -- Regulus Therapeutics ( RGLS ) said Tuesday it has completed enrollment in the phase 1b multiple-ascending dose trial of its investigational drug RGLS8429 drug to treat patients with autosomal dominant polycystic kidney disease, or ADPKD.

The company said 26 patients have been enrolled in the fourth and final cohort in the dosing trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS8429 in adult ADPKD patients compared to placebo.

Regulus said it expects topline data from a substantial number of the fourth cohort patients to be available early next year.

The company said results from each of the prior three cohorts in the study were positive, showing "continued evidence of a mechanistic dose response based on increase in urinary polycystins."

Shares of Regulus were down more than 5% in recent trading.

Price: 1.62, Change: -0.09, Percent Change: -5.26